Table 1.
Patient characteristics.
| n = 29 | |
|---|---|
| Age (±SD) | 73.9 (±8.8) |
| Male (%) | 21 (72.4) |
| BMI (±SD) | 21.9 (±4.5) |
| Disease type (%) | |
| IPF | 16 (55.2) |
| CPFE | 6 (20.7) |
| NSIP | 4 (13.8) |
| CVD-ILD | 2 (6.9) |
| PPFE | 1 (3.4) |
| Smoking status (%) | |
| Ex | 14 (48.3) |
| Never | 13 (44.8) |
| Current | 2 (6.9) |
| Respiratory function test(±SD) | |
| FVC | 2.26 (±1.08) |
| % FVC | 73.8 (±22.7) |
| FEV1.0 | 1.78 (±0.79) |
| FEV1.0% | 80.6 (±9.5) |
| % FEV1.0 | 74.2 (±21.1) |
| DLCO | 7.00 (±3.23) |
| DLCO/VA | 2.78 (±0.77) |
| % DLCO | 45.1 (±18.2) |
| % DLCO/VA | 64.7 (±19.2) |
| GAP score (±SD) | 3.5 (±1.2) |
| Pre-treatment (%) | |
| OCS | 11 (37.9) |
| Pirfenidone | 4 (13.8) |
| Nintedanib | 1 (3.4) |
| Home oxygen therapy | 3 (13.8) |
SD, standard deviation; IPF, idiopathic pulmonary fibrosis; CPFE, combined pulmonary fibrosis and emphysema; NSIP, nonspecific interstitial pneumonia; CVD-ILD, collagen vascular disease-interstitial lung disease; PPFE, pleuroparenchymal fibroelastosis; FVC, forced vital capacity; FEV1.0, forced expiratory volume in 1 s; DLCO, diffusing capacity of carbon monoxide; DLCO/VA, DLCO corrected for alveolar volume; OCS, oral corticosteroid; GAP, gender, age, physiology.